New data presented at the Alzheimer's Association International Conference indicates that pimavanserin leads to a robust reduction in the severity of psychosis symptoms during the 12 week open-label phase of the study, regardless of the underlying dementia subtype or the severity of participants' dementia.
Gum disease, especially the kind that is irreversible and causes tooth loss, may be associated with mild cognitive impairment and dementia 20 years later, according to a study published in the July 29, 2020, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A new blood test demonstrated remarkable promise in discriminating between persons with and without Alzheimer's disease and in persons at known genetic risk may be able to detect the disease as early as 20 years before the onset of cognitive impairment, according to a large international study published today in the Journal of the American Medical Association (JAMA) and simultaneously presented at the Alzheimer's Association International Conference.
Researchers at Washington University School of Medicine in St. Louis used mass spectrometry to discover that a form of the Alzheimer's protein tau is found at high levels in the blood of people in the earliest stages of Alzheimer's disease. The discovery could pave the way toward a blood-based test to diagnose the neurodegenerative disease before symptoms appear.
An extensive international study led by Tel Aviv University researchers found deposits of the tau protein typically found in Alzheimer's patients in tissues taken from the postmortem brain of a 7-year-old autistic child.
Research from the University of Sheffield's Neuroscience Institute examines how the routine use of Artificial Intelligence (AI) in healthcare could help to relieve the economic impact neurodegenerative diseases, such as Alzheimer's, put on the NHS
A simple blood test for Alzheimer's would be a great advance for individuals with -- and at risk for -- the disease, families, doctors and researchers.
Researchers compared the accuracy of the blood biomarker tau phosphorylated at threonine 217 (P-tau217) with other biomarkers for distinguishing Alzheimer from other neurodegenerative diseases in individuals with or at risk for dementia.
Two studies led by Stony Brook University researchers to be presented virtually at the Alzheimer's Association International Conference on July 28, 2020, indicate that World Trade Center (WTC) first responders are at risk for developing dementia.
Dozens of molecules may tangle up with rogue bundles of tau, a protein that normally gives nerve fibers structure, to cause brain cell damage that contributes to neurodegenerative diseases, a new study shows.